Susquehanna International Group, LLP Nektar Therapeutics Call Options Transaction History

Susquehanna International Group, LLP

$560 Billion
Q3 2024

Call Options

25 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$1.11 - $1.48 $12,321 - $16,428	-11,100 Reduced 35.92%	19,800 $25,000
Q2 2024 Aug 15, 2024	SELL	$0.9 - $1.83 $90,450 - $183,915	-100,500 Reduced 76.48%	30,900 $38,000
Q1 2024 May 07, 2024	BUY	$0.49 - $0.96 $64,386 - $126,144	131,400 New	131,400 $122,000
Q1 2023 May 16, 2023	BUY	$0.64 - $3.15 $10,624 - $52,290	16,600 New	16,600 $11,000
Q3 2022 Nov 14, 2022	SELL	$3.04 - $5.14 $40,432 - $68,362	-13,300 Reduced 36.14%	23,500 $75,000
Q2 2022 Aug 15, 2022	SELL	$3.17 - $6.17 $795,987 - $1.55 Million	-251,100 Reduced 87.22%	36,800 $140,000
Q1 2022 May 16, 2022	BUY	$4.16 - $13.72 $767,520 - $2.53 Million	184,500 Added 178.43%	287,900 $1.55 Million
Q4 2021 Feb 14, 2022	SELL	$10.83 - $18.41 $1.63 Million - $2.77 Million	-150,700 Reduced 59.31%	103,400 $1.4 Million
Q3 2021 Nov 15, 2021	BUY	$13.07 - $18.84 $2.21 Million - $3.18 Million	168,900 Added 198.24%	254,100 $4.56 Million
Q2 2021 Aug 11, 2021	BUY	$16.52 - $20.4 $416,304 - $514,079	25,200 Added 42.0%	85,200 $1.46 Million
Q1 2021 May 17, 2021	BUY	$16.56 - $25.46 $402,407 - $618,678	24,300 Added 68.07%	60,000 $1.2 Million
Q4 2020 Feb 16, 2021	SELL	$15.77 - $19.03 $1.01 Million - $1.21 Million	-63,800 Reduced 64.12%	35,700 $607,000
Q3 2020 Nov 16, 2020	BUY	$16.59 - $24.79 $4,977 - $7,437	300 Added 0.3%	99,500 $1.65 Million
Q2 2020 Aug 14, 2020	BUY	$16.86 - $23.44 $1.16 Million - $1.61 Million	68,600 Added 224.18%	99,200 $2.3 Million
Q1 2020 May 15, 2020	SELL	$14.47 - $27.96 $3.22 Million - $6.22 Million	-222,400 Reduced 87.91%	30,600 $546,000
Q4 2019 Feb 14, 2020	SELL	$15.87 - $23.12 $509,427 - $742,152	-32,100 Reduced 11.26%	253,000 $5.46 Million
Q3 2019 Nov 14, 2019	SELL	$16.91 - $36.27 $459,952 - $986,544	-27,200 Reduced 8.71%	285,100 $5.19 Million
Q2 2019 Aug 14, 2019	BUY	$31.0 - $36.3 $2.32 Million - $2.71 Million	74,700 Added 31.44%	312,300 $11.1 Million
Q1 2019 May 15, 2019	SELL	$31.58 - $46.35 $27.2 Million - $40 Million	-862,400 Reduced 78.4%	237,600 $7.98 Million
Q4 2018 Feb 14, 2019	BUY	$30.43 - $56.65 $13.8 Million - $25.8 Million	455,000 Added 70.54%	1,100,000 $36.2 Million
Q3 2018 Nov 14, 2018	SELL	$46.46 - $68.49 $10.5 Million - $15.5 Million	-226,800 Reduced 26.02%	645,000 $39.3 Million
Q2 2018 Aug 14, 2018	SELL	$46.25 - $104.45 $13 Million - $29.4 Million	-281,300 Reduced 24.4%	871,800 $42.6 Million
Q1 2018 May 15, 2018	BUY	$57.4 - $108.44 $46.9 Million - $88.6 Million	817,300 Added 243.39%	1,153,100 $123 Million
Q4 2017 Feb 14, 2018	BUY	$23.02 - $60.5 $4.1 Million - $10.8 Million	178,100 Added 112.94%	335,800 $20.1 Million
Q3 2017 Nov 14, 2017	BUY	$17.79 - $24.0 $2.81 Million - $3.78 Million	157,700	157,700 $3.79 Million

Others Institutions Holding NKTR

# of Institutions

145

Shares Held

139M

Call Options Held

32.6K

Put Options Held

14.1K

Deep Track Capital, LP Greenwich, CT

15.9M
Shares

$14.8 Million
0.76% of portfolio
Black Rock Inc. New York, NY

15.2M
Shares

$14.1 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

13.1M
Shares

$12.2 Million
0.0% of portfolio
Eventide Asset Management, LLC Boston, MA

9.4M
Shares

$8.74 Million
0.22% of portfolio
Samlyn Capital, LLC New York, NY

9.2M
Shares

$8.56 Million
0.19% of portfolio

View Full List

About NEKTAR THERAPEUTICS

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $174M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

More about NKTR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Account